These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 27270045)

  • 1. Modelling the Cost-Effectiveness of Delaying End-Stage Renal Disease.
    de Vries EF; Rabelink TJ; van den Hout WB
    Nephron; 2016; 133(2):89-97. PubMed ID: 27270045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F; Lau T; Luo N
    Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
    Teerawattananon Y; Mugford M; Tangcharoensathien V
    Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis.
    Littlewood KJ; Greiner W; Baum D; Zoellner Y
    BMC Nephrol; 2007 Jul; 8():9. PubMed ID: 17645811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of renal replacement therapy in Austria.
    Haller M; Gutjahr G; Kramar R; Harnoncourt F; Oberbauer R
    Nephrol Dial Transplant; 2011 Sep; 26(9):2988-95. PubMed ID: 21310740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of end stage renal disease treatment.
    de Wit GA; Ramsteijn PG; de Charro FT
    Health Policy; 1998 Jun; 44(3):215-32. PubMed ID: 10182294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic effects of treatment of chronic kidney disease with low-protein diet.
    Mennini FS; Russo S; Marcellusi A; Quintaliani G; Fouque D
    J Ren Nutr; 2014 Sep; 24(5):313-21. PubMed ID: 25167997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness analysis of treatment for end-stage renal disease].
    Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
    Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Bilous RW
    J Hum Hypertens; 2004 Oct; 18(10):733-8. PubMed ID: 15116142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.
    Brennan A; Akehurst R; Davis S; Sakai H; Abbott V
    Value Health; 2007; 10(1):32-41. PubMed ID: 17261114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of home nocturnal hemodialysis on end-stage renal disease therapies: a decision analysis.
    McFarlane PA; Bayoumi AM; Pierratos A; Redelmeier DA
    Kidney Int; 2006 Mar; 69(5):798-805. PubMed ID: 16407887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
    Govers TM; Hessels D; Vlaeminck-Guillem V; Schmitz-Dräger BJ; Stief CG; Martinez-Ballesteros C; Ferro M; Borque-Fernando A; Rubio-Briones J; Sedelaar JPM; van Criekinge W; Schalken JA
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):101-109. PubMed ID: 30127462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
    de Portu S; Citarella A; Cammarota S; Menditto E; Mantovani LG
    Clin Exp Hypertens; 2011; 33(3):174-8. PubMed ID: 21466388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic burden of end-stage renal disease in Canada.
    Zelmer JL
    Kidney Int; 2007 Nov; 72(9):1122-9. PubMed ID: 17700643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.